Cartesian Therapeutics, Inc. (RNAC) Dividend History

Company News

• Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

  Cartesian Therapeutics reported positive long-term results from its Phase 2b trial of Descartes-08 in myasthenia gravis, with plans to initiate a Phase 3 trial in Q2 2025. The company also expects to report preliminary data from a Phase 2 trial of Descartes-08 in systemic lupus erythematosus and initiate a Phase 2 pediatric basket trial in H2 2025. Cartesian had $182.1 million in cash as of March 31, 2025, expected to support operations into mid-2027.

  GlobeNewswire Inc.
• US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert

  US stock futures were volatile ahead of the market open, with experts advising investors to focus on capital preservation due to high uncertainty. The article discusses concerns over liquidity issues in the US banking system and the impact of tariffs on the markets.

  Benzinga

  Featured Companies: AAPL AEHR AMZN MMC NVDA QQQ RDW SPY TSLA
• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ACLX ALLO DTIL IPSC KYTX SANA
• By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights

  The global CAR-T cell therapy market is projected to grow from USD 2.7 Billion in 2024 to USD 8.7 Billion by 2034, exhibiting a CAGR of 1.80%. This innovative therapy has shown remarkable success in treating certain types of cancer, with ongoing technological advancements and research driving the market growth.

  GlobeNewswire Inc.

  Featured Companies: BLUE BMY CRBU MRK PFE
• Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

  Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.

  Zacks Investment Research

  Featured Companies: ALXO NERV